CA2758823A1 - Protein phosphatase 2a-activating agents - Google Patents

Protein phosphatase 2a-activating agents Download PDF

Info

Publication number
CA2758823A1
CA2758823A1 CA2758823A CA2758823A CA2758823A1 CA 2758823 A1 CA2758823 A1 CA 2758823A1 CA 2758823 A CA2758823 A CA 2758823A CA 2758823 A CA2758823 A CA 2758823A CA 2758823 A1 CA2758823 A1 CA 2758823A1
Authority
CA
Canada
Prior art keywords
chroman
enyl
yloxy
dimethyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2758823A
Other languages
English (en)
French (fr)
Inventor
Ching-Shih Chen
Dasheng Wang
Samuel K. Kulp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Publication of CA2758823A1 publication Critical patent/CA2758823A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/723,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
CA2758823A 2009-04-13 2010-04-13 Protein phosphatase 2a-activating agents Abandoned CA2758823A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16875909P 2009-04-13 2009-04-13
US61/168,759 2009-04-13
PCT/US2010/030799 WO2010120711A1 (en) 2009-04-13 2010-04-13 Protein phosphatase 2a-activating agents

Publications (1)

Publication Number Publication Date
CA2758823A1 true CA2758823A1 (en) 2010-10-21

Family

ID=42981438

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2758823A Abandoned CA2758823A1 (en) 2009-04-13 2010-04-13 Protein phosphatase 2a-activating agents

Country Status (6)

Country Link
US (1) US8461362B2 (https=)
EP (1) EP2419414A4 (https=)
JP (1) JP2012523458A (https=)
AU (1) AU2010236655A1 (https=)
CA (1) CA2758823A1 (https=)
WO (1) WO2010120711A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2414205T3 (es) 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
JP2012523458A (ja) 2009-04-13 2012-10-04 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション タンパク質ホスファターゼ2a活性化剤
CA2759011A1 (en) 2009-04-17 2010-10-21 The Ohio State University Research Foundation Antiadhesion agents
US8309768B2 (en) 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
WO2013181488A2 (en) * 2012-06-01 2013-12-05 The Ohio State University Research Foundation Inhibition of leukemic stem cells by pp2a activating agents
EP3240885B1 (en) * 2014-12-31 2024-11-13 Fluidigm Canada Inc. Structured biological samples for analysis by mass cytometry
CN108779073A (zh) * 2015-06-23 2018-11-09 凯斯西储大学 用于治疗癌症的组合物和方法
AU2016304856B8 (en) 2015-08-10 2021-02-18 Dana-Farber Cancer Institute, Inc. Mechanism of resistance to BET bromodomain inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2680749A (en) 1951-12-01 1954-06-08 Eastman Kodak Co Water-soluble tocopherol derivatives
DE2822324C3 (de) 1978-05-22 1981-02-26 Basf Ag, 6700 Ludwigshafen Herstellung von Vitamin-E-Trockenpulver
JPS59222415A (ja) 1983-05-31 1984-12-14 Kuraray Co Ltd 免疫調節剤
US4751224A (en) 1983-07-21 1988-06-14 Brown University Research Foundation Treatment of metastasis
ES2230571T3 (es) 1995-12-28 2005-05-01 Mitsubishi Pharma Corporation `composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria.
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6770672B1 (en) 1998-09-23 2004-08-03 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
JP2002526446A (ja) 1998-09-23 2002-08-20 リサーチ ディベロップメント ファンデーション トロフェロール、トコトリエノール、その他のクロマン及び側鎖誘導体、並びにそれらの利用
KR100847678B1 (ko) 2000-02-11 2008-07-23 리서치 디벨럽먼트 파운데이션 토코페롤, 토코트리에놀, 다른 크로만 및 측쇄 유도체, 및이들의 용도
JP2002121132A (ja) * 2000-08-09 2002-04-23 Showa Denko Kk 発がん抑制剤および発がん抑制方法
US20040248971A1 (en) 2001-07-27 2004-12-09 Shuyuan Yeh Use of vitamin e succinate and antiandrogen combination
US6858227B1 (en) 2001-11-21 2005-02-22 Sonus Pharmaceuticals, Inc. Vitamin E conjugates
US20050215531A1 (en) 2002-05-16 2005-09-29 Thomas Baumruker Use of edg receptor binding agents in cancer
WO2005025553A2 (en) 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
KR101346527B1 (ko) 2005-12-15 2013-12-31 미쓰비시 타나베 파마 코퍼레이션 아민 화합물 및 그 의약 용도
AU2007217810B2 (en) 2006-02-21 2012-10-11 The Ohio State University Research Foundation Anticancer agents
ES2414205T3 (es) 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
ES2393631T3 (es) 2006-08-17 2012-12-26 University Of Chicago Tratamiento de enfermedades inflamatorias
NZ575920A (en) * 2006-09-15 2012-08-31 Stephen John Ralph Pro-oxidant anti-cancer compounds
JP4481316B2 (ja) * 2007-01-09 2010-06-16 株式会社エヌ・ティ・ティ・ドコモ ユーザ装置および送信方法
TWI439263B (zh) 2007-06-14 2014-06-01 Mitsubishi Tanabe Pharma Corp 胺化合物及其醫藥用途
WO2010042998A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
JP2012523458A (ja) 2009-04-13 2012-10-04 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション タンパク質ホスファターゼ2a活性化剤
CA2759011A1 (en) 2009-04-17 2010-10-21 The Ohio State University Research Foundation Antiadhesion agents

Also Published As

Publication number Publication date
US8461362B2 (en) 2013-06-11
EP2419414A1 (en) 2012-02-22
US20100267673A1 (en) 2010-10-21
WO2010120711A1 (en) 2010-10-21
AU2010236655A1 (en) 2011-11-17
JP2012523458A (ja) 2012-10-04
EP2419414A4 (en) 2013-12-04

Similar Documents

Publication Publication Date Title
US8461362B2 (en) Protein phosphatase 2A-activating agents
Yan et al. Synthesis, evaluation, and mechanism study of novel indole-chalcone derivatives exerting effective antitumor activity through microtubule destabilization in vitro and in vivo
Nambiar et al. Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1
Patil et al. Phosphonooxymethyl prodrug of triptolide: Synthesis, physicochemical characterization, and efficacy in human colon adenocarcinoma and ovarian cancer xenografts
US9757350B2 (en) Small molecule inhibitors of replication protein A that also act synergistically with cisplatin
Monteiro et al. DUSP3/VHR: a druggable dual phosphatase for human diseases
Wang et al. Inhibition of heat shock induction of heat shock protein 70 and enhancement of heat shock protein 27 phosphorylation by quercetin derivatives
AU2015314772A1 (en) Compositions and methods for treatment of prostate carcinoma
CN107921015A (zh) 具有脂肪组织甘油三酯降解作用的壬二酸组合物
Mahata et al. PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer
US7026346B2 (en) Compounds and methods for inducing apoptosis in proliferating cells
EP2418948B1 (en) Antiadhesion agents
JP2015098492A (ja) チアゾリジンジオンエネルギー制限模倣剤
WO2012087889A2 (en) Dna methylation inhibitors
AU2007217810B2 (en) Anticancer agents
US8519007B2 (en) Use certain diterpene compounds in the treatment of androgen receptor-associated diseases
Hernández‐Velázquez et al. Multidrug Resistance Reversed by Maleimide Interactions. A Biological and Synthetic Overview for an Emerging Field
US10188743B2 (en) Cytisine-linked isoflavonoid antineoplastic agents for the treatment of cancer
EP2909171B1 (fr) Composés 3,4-bis(catéchol)pyrrole n-substitués, leur préparation et utilisation dans le traitement du cancer
WO2016160819A1 (en) Method for the treatment of nf1-or ras-associated disorders
US20140031388A1 (en) Akt inactivation by tocopheryl derivatives
US20060142368A1 (en) Compounds and methods for inducing apoptosis in proliferating cells
Estévez Braun et al. 1, 2, 3-Triazole-totarol conjugates as potent PIP5K1α lipid kinase inhibitors
Viehoever et al. Therapeutic interference of SREBP-mediated lipid metabolism by E-Xanthohumol attenuates prostate cancer progression
US9156790B2 (en) Anticancer P21-activated kinase inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160413